



LUMIXA[®]
ADVANCED



PRESERVATIVE FREE
NEW NOVELIA[®] BOTTLE



A COMPLETE TEAR SUBSTITUTE
FOR THE TREATMENT OF DRY EYE

Triple Layer Action for Triple Targeted Protection

Triple Layer Action for Triple Targeted Protection

86% of patients with dry eye disease are effected by Meibomian Gland Dysfunction(MGD).⁷


MGD is associated with multiple pathological mechanism including inflammation, microbial factors, and lipid deficiencies.

LUMIXA®ADVANCED provides a complete tear substitute for the treatment of dry eye.



SYNERGISTIC ACTION OF 3 COMPONENTS FOR 3 LAYERS OF TEAR FILM⁵⁻⁶


- **CROSS-LINKED HYALURONIC ACID(0.15%)**
- **LIPOSOMES (0.6%)**
- **CROCIN**, unique water-soluble light-activable carotenoid



Triple Layer Action for Triple Targeted Protection

LUMIXA® ADVANCED has 7 Folds greater muco-adhesivity compared to control⁹

MUCO-ADHESIVITY




Ref. Molecules. 2021;26(4):849.

Fig. - increase of muco-adhesiveness of a formulation based on crocin + cross-linked hyaluronic acid + liposomes (LUMIXA® ADVANCED) before and after light exposure in comparison to CXL hyaluronic acid.²

LUMIXA® ADVANCED formulation provides superiority to Hyaluronic Acid 0.2% in stabilization of tear film and improvement of dry eye symptoms after one month of therapy⁸



TEAR BREAKUP TIME (TBUT)¹



Triple Layer Action for Triple Targeted Protection

- Multidose, preservatives free, **SOFTER AND WITH A TIP** for easy administration ¹⁰
- Formulation with, **PHOTOACTIVE CROCIN, 0.15%** high-mw **HA CXL** and **LIPOSOMES** ¹⁰
- **LUMIXA® ADVANCED** Novelia® bottle **REMAINS STERILE FOR UP TO 60 DAYS** after first use ¹⁰
- **PRESERVATIVE-FREE** protective ophthalmic solution ¹⁰
- A complete **TEAR SUBSTITUTE** for dry eye treatment



PRESERVATIVE FREE
NEW NOVELIA® BOTTLE



Composition

0.15% Cross-linked hyaluronic acid sodium salt, liposomes, crocin, edetate sodium, buffered isotonic solution pH 7.2 q.s. in 100 ml.

Indications

Symptomatic treatment for dry eye syndrome

Also suitable for the corneal protection as a tear substitute after surgery, ocular trauma, or in case of environmental or visual stress

Application method

Instill one or two drops in each eye more times a day or according to medical advice.

Precautions

Store the product at a temperature between 8 and 25°C

Do not use the product after 60 days from opening

Make sure that the tip of the bottle does not come in contact with the eye

Administer the product at least 5 minutes apart from the Administration of other products for Topical ophthalmic use

Do not use the product if you are allergic or have a known hypersensitivity to any of the components

In case of adverse reaction, discontinue use and consult your doctor

References

(1)Int J Ophthalmol. 2020 Sep 18;13(9):1368-1373. doi: 10.18240/ijo.2020.09.05. eCollection 2020. (2)Ali S, Davinelli S, Mencucci R, et al. Crosslinked Hyaluronic Acid with Liposomes and Crocin Confers Cytoprotection in an Experimental Model of Dry Eye. Molecules. 2021 Feb 6;26(4):849. doi: 10.3390/molecules26040849. (3)Modern management of MGD. Review of ophthalmology/CMSDocuments/2019/07/J_J_MGD_Roi. (4)Int J Ophthalmol. 2020 Sep 18;13(9):1368-1373. doi: 10.18240/ijo.2020.09.05. eCollection 2020. (5)Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. (2017) 15:334-65. 10.1016/j.jtos.2017.05.003. (6)Sánchez-González JM, De-Hita-Cantalejo C, Sánchez-González MC. Int J Ophthalmol. 2020;13. (7)10.1097/ICO.0b013e318225415a. (8)10.3390/molecules26040849. (9)Sánchez-González JM, De-Hita-Cantalejo C, Sánchez-González MC. Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction. Int J Ophthalmol. 2020;13(9):1368-1373. (10)Lumixa instructions for use (IFU)